Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-23-012129
Filing Date
2023-08-11
Accepted
2023-08-11 16:10:19
Documents
1
Period of Report
2023-08-11

Document Format Files

Seq Description Document Type Size
1 form4-08112023_040807.html 4  
1 form4-08112023_040807.xml 4 5173
  Complete submission text file 0001415889-23-012129.txt   6564
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Issuer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET, SUITE 600 CAMBRIDGE MA 02142
Business Address
Ashton-Rickardt Philip (Reporting) CIK: 0001866197 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39746 | Film No.: 231164160